Search

Your search keyword '"Waters, David D."' showing total 182 results
Start Over Author "Waters, David D." Publisher elsevier bv
182 results on '"Waters, David D."'

3. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Author

Tardif, Jean-Claude, primary, Bouabdallaoui, Nadia, additional, L'Allier, Philippe L, additional, Gaudet, Daniel, additional, Shah, Binita, additional, Pillinger, Michael H, additional, Lopez-Sendon, Jose, additional, da Luz, Protasio, additional, Verret, Lucie, additional, Audet, Sylvia, additional, Dupuis, Jocelyn, additional, Denault, André, additional, Pelletier, Martin, additional, Tessier, Philippe A, additional, Samson, Sarah, additional, Fortin, Denis, additional, Tardif, Jean-Daniel, additional, Busseuil, David, additional, Goulet, Elisabeth, additional, Lacoste, Chantal, additional, Dubois, Anick, additional, Joshi, Avni Y, additional, Waters, David D, additional, Hsue, Priscilla, additional, Lepor, Norman E, additional, Lesage, Frédéric, additional, Sainturet, Nicolas, additional, Roy-Clavel, Eve, additional, Bassevitch, Zohar, additional, Orfanos, Andreas, additional, Stamatescu, Gabriela, additional, Grégoire, Jean C, additional, Busque, Lambert, additional, Lavallée, Christian, additional, Hétu, Pierre-Olivier, additional, Paquette, Jean-Sébastien, additional, Deftereos, Spyridon G, additional, Levesque, Sylvie, additional, Cossette, Mariève, additional, Nozza, Anna, additional, Chabot-Blanchet, Malorie, additional, Dubé, Marie-Pierre, additional, Guertin, Marie-Claude, additional, and Boivin, Guy, additional

Published
2021
Full Text
View/download PDF

16. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib

Author

Tardif, Jean-Claude, primary, Dubé, Marie-Pierre, additional, Pfeffer, Marc A., additional, Waters, David D., additional, Koenig, Wolfgang, additional, Maggioni, Aldo P., additional, McMurray, John J.V., additional, Mooser, Vincent, additional, White, Harvey D., additional, Heinonen, Therese, additional, Black, Donald M., additional, and Guertin, Marie-Claude, additional

Published
2020
Full Text
View/download PDF

22. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)

Author

Ong, Kwok Leung, primary, Hui, Nicholas, additional, Januszewski, Andrzej S., additional, Kaakoush, Nadeem O., additional, Xu, Aimin, additional, Fayyad, Rana, additional, DeMicco, David A., additional, Jenkins, Alicia J., additional, Keech, Anthony C., additional, Waters, David D., additional, Barter, Philip J., additional, and Rye, Kerry-Anne, additional

Published
2019
Full Text
View/download PDF

25. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Author

Swerdlow, Daniel I., Preiss, David, Kuchenbaecker, Karoline B., Holmes, Michael V., Engmann, Jorgen E. L., Shah, Tina, Sofat, Reecha, Stender, Stefan, Johnson, Paul C. D., Scott, Robert A., Leusink, Maarten, Verweij, Niek, Sharp, Stephen J., Guo, Yiran, Giambartolomei, Claudia, Chung, Christina, Peasey, Anne, Amuzu, Antoinette, Li, KaWah, Palmen, Jutta, Howard, Philip, Cooper, Jackie A., Drenos, Fotios, Lowe, Gordon, Gallacher, John, Stewart, Marlene C. W., Tzoulaki, Ioanna, Buxbaum, Sarah G., van der A, Daphne L., Forouhi, Nita G., Onland-Moret, N. Charlotte, van der Schouw, Yvonne T., Hubacek, Jaroslav A., Kubinova, Ruzena, Baceviciene, Migle, Tamosiunas, Abdonas, Pajak, Andrzej, Topor-Madry, Roman, Stepaniak, Urszula, Malyutina, Sofia, Baldassarre, Damiano, Sennblad, Bengt, Tremoli, Elena, de Faire, Ulf, Veglia, Fabrizio, Ford, Ian, Wouter Jukema, J., Westendorp, Rudi G. J., de Borst, Gert Jan, de Jong, Pim A., Algra, Ale, Spiering, Wilko, H Maitland-van der Zee, Anke H., Klungel, Olaf H., de Boer, Anthonius, Doevendans, Pieter A., Eaton, Charles B., Robinson, Jennifer G., Duggan, David, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, Kjekshus, John, Downs, John R., Gotto, Antonio M., Keech, Anthony C., Marchioli, Roberto, Tognoni, Gianni, Sever, Peter S., Poulter, Neil R., Waters, David D., Pedersen, Terje R., Amarenco, Pierre, Nakamura, Haruo, McMurray, John J. V., Lewsey, James D., Chasman, Daniel I., Ridker, Paul M., Maggioni, Aldo P., Tavazzi, Luigi, Ray, Kausik K., Kondapally Seshasai, Sreenivasa Rao, Manson, JoAnn E., Price, Jackie F., Whincup, Peter H., Morris, Richard W., Lawlor, Debbie A., Smith, George Davey, Ben-Shlomo, Yoav, Schreiner, Pamela J., Fornage, Myriam, Siscovick, David S., Cushman, Mary, Kumari, Meena, Wareham, Nick J., Verschuren, W. M. Monique, Redline, Susan, Patel, Sanjay R., Whittaker, John C., Hamsten, Anders, Delaney, Joseph A., Dale, Caroline, Gaunt, Tom R., Wong, Andrew, Kuh, Diana, Hardy, Rebecca, Kathiresan, Sekar, Castillo, Berta A., van der Harst, Pim, Brunner, Eric J., Tybjaerg-Hansen, Anne, Marmot, Michael G., Krauss, Ronald M., Tsai, Michael, Coresh, Josef, Hoogeveen, Ronald C., Psaty, Bruce M., Lange, Leslie A., Hakonarson, Hakon, Dudbridge, Frank, Humphries, Steve E., Talmud, Philippa J., Kivimäki, Mika, Timpson, Nicholas J., Langenberg, Claudia, Asselbergs, Folkert W., Voevoda, Mikhail, Bobak, Martin, Pikhart, Hynek, Wilson, James G., Reiner, Alex P., Keating, Brendan J., Hingorani, Aroon D., Sattar, Naveed, Li, Yun R., Imperial College Healthcare NHS Trust- BRC Funding, National Institute for Health Research, Cardiovascular Centre (CVC), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Sharp, Stephen [0000-0003-2375-1440], Forouhi, Nita [0000-0002-5041-248X], Wareham, Nicholas [0000-0003-1422-2993], Langenberg, Claudia [0000-0002-5017-7344], and Apollo - University of Cambridge Repository

Subjects
Male, STATIN THERAPY, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, DISEASE, Body Mass Index, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Medicine, HIGH-DOSE ATORVASTATIN, Randomized Controlled Trials as Topic, RISK, 0303 health sciences, MAGIC Consortium, Articles, 11 Medical And Health Sciences, General Medicine, Middle Aged, 3. Good health, MENDELIAN RANDOMIZATION, Female, Life Sciences & Biomedicine, medicine.medical_specialty, Statin, medicine.drug_class, DIAGRAM Consortium, Placebo, Polymorphism, Single Nucleotide, 03 medical and health sciences, Medicine, General & Internal, General & Internal Medicine, Internal medicine, Diabetes mellitus, Humans, Genetic Testing, METAANALYSIS, Aged, 030304 developmental biology, Science & Technology, business.industry, Cholesterol, Body Weight, Cholesterol, HDL, Type 2 Diabetes Mellitus, Cholesterol, LDL, Odds ratio, InterAct Consortium, medicine.disease, R1, PREVENTION, BODY-MASS INDEX, Endocrinology, Diabetes Mellitus, Type 2, chemistry, Hydroxymethylglutaryl CoA Reductases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, LDL CHOLESTEROL, business, ASSOCIATION ANALYSES, Body mass index
Abstract

Background: Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.Methods: We used single nucleotide polymorphisms in the HMGCR gene, rs17238484 (for the main analysis) and rs12916 (for a subsidiary analysis) as proxies for HMGCR inhibition by statins. We examined associations of these variants with plasma lipid, glucose, and insulin concentrations; bodyweight; waist circumference; and prevalent and incident type 2 diabetes. Study-specific effect estimates per copy of each LDL-lowering allele were pooled by meta-analysis. These findings were compared with a meta-analysis of new-onset type 2 diabetes and bodyweight change data from randomised trials of statin drugs. The effects of statins in each randomised trial were assessed using meta-analysis.Findings: Data were available for up to 223 463 individuals from 43 genetic studies. Each additional rs17238484-G allele was associated with a mean 0·06 mmol/L (95% CI 0·05–0·07) lower LDL cholesterol and higher body weight (0·30 kg, 0·18–0·43), waist circumference (0·32 cm, 0·16–0·47), plasma insulin concentration (1·62%, 0·53–2·72), and plasma glucose concentration (0·23%, 0·02–0·44). The rs12916 SNP had similar effects on LDL cholesterol, bodyweight, and waist circumference. The rs17238484-G allele seemed to be associated with higher risk of type 2 diabetes (odds ratio [OR] per allele 1·02, 95% CI 1·00–1·05); the rs12916-T allele association was consistent (1·06, 1·03–1·09). In 129 170 individuals in randomised trials, statins lowered LDL cholesterol by 0·92 mmol/L (95% CI 0·18–1·67) at 1-year of follow-up, increased bodyweight by 0·24 kg (95% CI 0·10–0·38 in all trials; 0·33 kg, 95% CI 0·24–0·42 in placebo or standard care controlled trials and −0·15 kg, 95% CI −0·39 to 0·08 in intensive-dose vs moderate-dose trials) at a mean of 4·2 years (range 1·9–6·7) of follow-up, and increased the odds of new-onset type 2 diabetes (OR 1·12, 95% CI 1·06–1·18 in all trials; 1·11, 95% CI 1·03–1·20 in placebo or standard care controlled trials and 1·12, 95% CI 1·04–1·22 in intensive-dose vs moderate dose trials).Interpretation: The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition.Funding: The funding sources are cited at the end of the paper.

Published
2015

29. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

Author

Arsenault, Benoit J., primary, Petrides, Francine, additional, Tabet, Fatiha, additional, Bao, Weihang, additional, Hovingh, G. Kees, additional, Boekholdt, S. Matthijs, additional, Ramin-Mangata, Stéphane, additional, Meilhac, Olivier, additional, DeMicco, David, additional, Rye, Kerry-Anne, additional, Waters, David D., additional, Kastelein, John J.P., additional, Barter, Philip, additional, and Lambert, Gilles, additional

Published
2018
Full Text
View/download PDF

32. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

Author

Faergeman, Ole, Holme, Ingar, Fayyad, Rana, Bhatia, Sonal, Grundy, Scott M, Kastelein, John J P, LaRosa, John C, Larsen, Mogens Lytken, Lindahl, Christina, Olsson, Anders G, Tikkanen, Matti J, Waters, David D, Pedersen, Terje R, IDEAL and TNT Trials, Steering Committees, ACS - Amsterdam Cardiovascular Sciences, and Vascular Medicine

Subjects
Adult, Male, medicine.medical_specialty, Apolipoprotein B, Atorvastatin, Myocardial Infarction, Coronary Artery Disease, Cohort Studies, Coronary artery disease, Predictive Value of Tests, Recurrence, Risk Factors, Internal medicine, Diabetes mellitus, medicine, Humans, Myocardial infarction, Triglycerides, Aged, Proportional Hazards Models, Retrospective Studies, biology, business.industry, Hazard ratio, nutritional and metabolic diseases, Middle Aged, medicine.disease, Cholesterol, Simvastatin, Cardiology, biology.protein, Female, lipids (amino acids, peptides, and proteins), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, Body mass index, medicine.drug
Abstract

We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials. The trials compared atorvastatin 80 mg/day with moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT) in patients with clinically evident coronary heart disease or a history of myocardial infarction. The outcome measurement in the present research was CVE occurring after the first year of the trial. After adjusting for age, gender, and study, risk of CVEs increased with increasing TGs (p

Published
2009

44. Reply

Author

Boekholdt, S. Matthijs, primary, Hovingh, G. Kees, additional, Waters, David D., additional, Grundy, Scott M., additional, and Kastelein, John J.P., additional

Published
2015
Full Text
View/download PDF

46. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

Author

Boekholdt, S. Matthijs, primary, Hovingh, G. Kees, additional, Mora, Samia, additional, Arsenault, Benoit J., additional, Amarenco, Pierre, additional, Pedersen, Terje R., additional, LaRosa, John C., additional, Waters, David D., additional, DeMicco, David A., additional, Simes, R. John, additional, Keech, Antony C., additional, Colquhoun, David, additional, Hitman, Graham A., additional, Betteridge, D. John, additional, Clearfield, Michael B., additional, Downs, John R., additional, Colhoun, Helen M., additional, Gotto, Antonio M., additional, Ridker, Paul M., additional, Grundy, Scott M., additional, and Kastelein, John J.P., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results